Observational studyInternational journal of chronic obstructive pulmonary disease2026
Irisin, BMI, and SII as Predictors of Frequent Acute Exacerbations in COPD: Development of a Predictive Nomogram.
Observational study in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Frequent acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with poor prognosis, but objective and easily applicable predictors remain limited. This study aimed to investigate the association of Irisin, body mass index (BMI), and systemic immune-inflammation index (SII) with frequent acute exacerbations in COPD and to develop a predictive nomogram. Methods: This single-center retrospective-prospective observational study included 96 patients hospitalized with acute exacerbation of COPD (AECOPD) between March 2023 and March 2025. Frequent exacerbation was defined as ≥2 acute exacerbations or ≥1 hospitalization for AECOPD within one year. Patients were classified into the frequent exacerbation group (n=34) and non-frequent exacerbation group (n=62). Clinical data and serum Irisin levels were collected. Group comparisons, correlation analysis, univariate and multivariable logistic regression analyses were performed, and a nomogram was developed. Model performance was evaluated using receiver operating characteristic (ROC) analysis, calibration curve, bootstrap internal validation, and decision curve analysis. Results: Compared with the non-frequent exacerbation group, the frequent exacerbation group had lower Irisin and BMI levels and higher white blood cell count, neutrophil count, and SII. Multivariable logistic regression showed that Irisin (OR=0.981, 95% CI: 0.974-0.989) and BMI (OR=0.980, 95% CI: 0.963-0.998) were independently associated with a lower risk of frequent exacerbations, whereas lnSII (OR=1.117, 95% CI: 1.012-1.234) was associated with a higher risk. The combined model yielded an area under the ROC curve of 0.856 (95% CI: 0.780-0.933), showing better discrimination than Irisin alone. Calibration and decision curve analyses suggested favorable internal performance. Conclusion: Irisin, BMI, and SII were associated with frequent acute exacerbations in COPD. The combined nomogram may provide a preliminary reference for risk stratification, but external validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.